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Non-insulin-dependent diabetes mellitus (NIDDM)
is a well-known risk factor for cardiovascular disease
and stroke [1–3]. Apart from the obvious lesions
caused by strokes, also subtle neurochemical, electro-
physiologic and structural changes have been found
in brains of patients with NIDDM [3–5]. Neuropsy-
chologic test profiles of NIDDM patients, compared
to those of healthy or hospital control subjects,
showed decreased cognitive functions [6–9]. Several
authors suggested that, analogous to its association
with cerebral infarction, NIDDM is related to vascu-
lar dementia [10, 11]. However, the extent to which
NIDDM is associated with other dementia subtypes,
in particular Alzheimer’s disease (AD), is unclear
[12–15].
We examined the association between NIDDM
and prevalent dementia in a large population-based
study.
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Summary Dementia and non-insulin-dependent dia-
betes mellitus (NIDDM) are highly prevalent disor-
ders in the elderly. Diabetes has repeatedly been re-
ported to affect cognition, but its relation with de-
mentia is uncertain. We therefore studied the associa-
tion between diabetes and dementia in the Rotter-
dam Study, a large population-based study in the el-
derly. Of 6330 participants, aged 55 to 99 years old,
complete information on diabetes and presence of
dementia was available. Diabetes was diagnosed as
use of anti-diabetes medication or random or post-
load serum glucose over 11 mmol/l. Dementia was di-
agnosed through a stepped approach, including a sen-
sitive screening of all participants and a comprehen-
sive diagnostic work-up. Diabetes was present in 724
(11.4%) subjects. Of the 265 dementia patients 59
(22.3%) had diabetes. Multiple logistic regression
analyses, adjusting for age and sex differences, re-
vealed a positive association between diabetes and
dementia (odds ratio: 1.3, 95% confidence interval:
1.0–1.9). In particular, strong associations were found
between dementia and diabetes treated with insulin
(odds ratio: 3.2, 95% confidence interval: 1.4–7.5).
The relation was strongest with vascular dementia,
but was also observed with Alzheimer’s disease.
These associations were independent of educational
attainment, smoking, body mass index, atherosclero-
sis, blood pressure and antihypertensive drug treat-
ment, and could not be explained by clinical cerebral
infarctions. The results suggest that NIDDM is asso-
ciated with dementia. Alzheimer’s disease may be
more frequent in elderly diabetic patients treated
with insulin. [Diabetologia (1996) 39: 1392–1397]
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Subjects and methods
Subjects. The Rotterdam Study is a population-based prospec-
tive follow-up study in which several important diseases of the
elderly are investigated [16]. The study focuses on four groups
of diseases: neurological, cardiovascular, locomotor and oph-
thalmologic. All inhabitants of Ommoord, a suburb of Rotter-
dam, aged 55 years and older, including those living in institu-
tions, were invited to participate in the study. Of the 10 275 eli-
gible subjects, 7983 participated in the Rotterdam Study. Be-
tween 1990 and 1993 participants were extensively interviewed
at their homes and examined at the research centre in order to
collect baseline data and to ascertain their health status. De-
mentia status was missing in 455 (6%) subjects, mainly because
they refused the cognitive screening test. Blood glucose mea-
surements started in July 1990, after the pilot phase in which
544 randomly choosen participants were examined. Of the
7439 subjects who were examined since then, blood glucose
measurements were absent in 821 (11%), mainly due to logis-
tic or technical problems. In the present analyses 6330 partici-
pants (85%), with complete information on drug use, blood
glucose measurements and the presence of dementia were in-
cluded. Dementia and diabetes assessments took place com-
pletely independent of each other without prior knowledge of
the study physicians about which associations would later be
tested.
Examinations. The prevalence of dementia was assessed using a
three-phase approach [17]. With a brief cognitive test, the com-
bined Mini Mental State Examination (MMSE) [18] and Geri-
atric Mental State schedule (GMS-A, organic level) [19], the
population was screened for dementia. This test was adminis-
tered by trained research assistants. Screen positive subjects
(Mini Mental State Examination score below 26 or Geriatric
Mental State score above 0) were subsequently examined by a
physician with the Cambridge Examination for Mental Disor-
ders of the Elderly diagnostic interview [20]. Participants who
were suspected of dementia after this interview underwent an
extensive examination which included examinations by a neu-
rologist, a neuropsychologist and brain magnetic resonance im-
aging. Based on all available information a diagnosis of demen-
tia was then made according to Diagnostic and Statistical Man-
ual of mental disorders criteria [21], with a subdiagnosis of AD
based on National Institute of Neurological and Communica-
tive Disorders and Stroke and Alzheimer’s Disease and Re-
lated Disorders Association criteria [22] and of vascular de-
mentia in accordance with National Institute of Neurological
Disorders and Stroke and Association Internationale pour la
Recherche et l’Enseignement en Neurosciences criteria [23].
Current drug use was assessed during the initial home inter-
view. Participants were asked to show all medication they were
using. Of institutionalised participants, medication was re-
ported by the medical staff. From all participants blood was
drawn by venipuncture and allowed to coagulate for 30 min.
Subjects without anti-diabetic medication subsequently re-
ceived a 200 ml glucose drink which contained 75 g of glucose;
a second blood sample was obtained 2 h later. Random and
post-load glucose levels were measured by the glucose hexoki-
nase method. Diabetes was defined as the use of anti-diabetic
medication or at least one glucose value greater than
11 mmol/l.
Level of education was assessed during the initial interview
and grouped in four levels, from primary school only, to college
and higher. Smoking habits were assessed during interview and
categorised as never, former or current smoking. Body mass
index was calculated by dividing weight through the square of
height and expressed as kg/m2. Systolic blood pressure was
measured with a random zero sphygmomanometer. The an-
kle-to-brachial index (the ratio of the systolic blood pressure
measured at the ankle and the upper arm) was used as a mea-
sure of peripheral atherosclerosis: a ratio of 0.9 or below was
considered positive [24]. Resting ECGs were analysed by the
Modular ECG Analysis System (MEANS) computer program
[25]. This program contains modules for rhythm classification,
contour analyses and Minnesota coding and was shown to
give very accurate ECG diagnoses [26]. The presence of coro-
nary artery disease, was approximated by the program’s diag-
nosis of probable or definite myocardial infarction, which was
used as a second measure of atherosclerosis. A history of
stroke was determined through interview or in dementia pa-
tients through informant interview, and verified with medical
records.
Statistical analysis
The association between NIDDM and dementia was examined
by calculating odds ratios (OR) by multivariate logistic regres-
sion with dementia as the dependent, and NIDDM, age and
sex as independent variables in the model. In all regression
models age was treated as a continuous variable. To assess
whether this relation was different across levels of severity of
NIDDM, we performed subanalyses in which we compared pa-
tients without anti-diabetes medication, patients using oral
anti-diabetes medication and patients treated with insulin, to
non-diabetic subjects. In addition to age and sex, we included
educational level, smoking, body mass index, atherosclerosis,
systolic blood pressure level and antihypertensive drug treat-
ment to the regression model in order to adjust for confound-
ing by these variables. To examine whether the association
could be explained by an increased stroke risk in diabetic pa-
tients, the analyses were repeated in subjects without stroke
history.
Results
Of the 6330 subjects in this study, 265 (4.2%) were di-
agnosed with dementia (Table 1). In 194 the demen-
tia was of the Alzheimer’s disease (AD) type (73%),
44 subjects had a vascular dementia (17%), and
27 had other dementias (10%). Of the AD patients
32 (16%) had cerebrovascular disease, based on a
history of stroke or cerebral magnetic resonance im-
aging findings, that was considered not directly aetio-
logically related to the dementia. Ages ranged from
55 to 99 years. Dementia prevalence increased shar-
ply with age: from 0.3% in the age group 55–64 years
to 30% in subjects of 85 and older. Since the older
age groups had higher proportions of women, there
were relatively more women with dementia. The
prevalence of NIDDM also increased with age: from
6% in the age group of 55–64 years to 22% in sub-
jects of 85 and older. NIDDM was diagnosed in
11% of the non-demented participants and in 22%
of the dementia patients. Among AD, vascular and
other dementia patients, 21, 30 and 19 % had
NIDDM, respectively. Of the NIDDM patients 34%
were using oral medication and 10% received insulin
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treatment. These proportions were similar among the
dementia patients. After adjustment for age and sex
differences, dementia patients had a significantly
higher serum glucose level, a lower body mass index
and systolic blood pressure, more frequent history of
stroke and a lower educational status than subjects
without dementia.
Table 2 shows the association between diabetes
and dementia for the total population and for men
and women separately. In women a significant associ-
ation with dementia was observed (OR: 1.5, 95%
confidence interval (CI) 1.0–2.2). However, NIDDM
treated with insulin was strongly correlated to de-
mentia in both men and women (OR: 3.2, 95% CI:
1.4–7.5, for both sexes combined). Additional adjust-
ments for possible confounders only marginally al-
tered the associations.
Both NIDDM and dementia patients more often
had stroke histories than participants without diabe-
tes or dementia. Excluding subjects with a history of
stroke however, did not change the association
between diabetes and dementia (OR: 1.3, 95% CI:
0.9–1.9 for overall NIDDM and OR: 3.0, 95% CI:
1.1–7.8 for NIDDM treated with insulin).
In Table 3 the associations between diabetes and
dementia subtypes are given. The association of insu-
lin-treated NIDDM to dementia was observed for all
subtypes, but was strongest for vascular dementia. Di-
abetes treated with oral medication was significantly
associated with vascular dementia. Again additional
adjustments for confounders resulted in essentially
similar associations.
Discussion
In this study we investigated the relation between
NIDDM and dementia. NIDDM treated with insulin
was strongly associated with dementia and this was
independent of level of education, smoking, body
mass index, presence of atherosclerosis, systolic
blood pressure and antihypertensive medication.
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Table 1. Characteristics of the total study population, of demented and non-demented subjects
Total population Non-demented
subjects
Demented
subjects
Adjusted differ-
ence between
non-demented and
demented subjectsb
(95% CI)
Population size 6330 6065 265
Female (%) 59.4 58.9 71.3
Age (years) 69.3 – 9.1 68.7 – 8.7 83.3 – 7.8
Random serum glucose (mmol/l) 6.9 – 2.7 6.9 – 2.6 7.9 – 3.9 0.5 (0.1–0.8)
NIDDM (%) 11.4 11.0 22.3 3.2 ( - 0.4–7.8)
no drug treatment (% of NIDDM) 55.9 56.1 54.2
oral medication (% of NIDDM) 33.7 33.8 32.2
insulin treatment (% of NIDDM) 10.4 10.1 13.6
Only primary education or less (%) 24.2 22.6 64.8 20.2 (13.0–27.8)
Ever smoking (%) 64.3 65.0 47.2 - 4.8 ( - 12.5–2.3)
Body mass index (kg/m2) 26.3 – 3.7 26.3 – 3.7 25.3 – 3.9 - 1.2 ( - 1.8– - 0.7)
Peripheral atherosclerosis (%) 18.4 17.1 47.8 4.2 ( - 0.5–9.9)
ECG myocardial infarction (%) 9.2 8.9 17.2 2.4 ( - 0.8–6.7)
Systolic blood pressure (mmHg) 139.5 – 22.6 139.4 – 22.5 141.5 – 24.6 - 7.6 ( - 10.6– - 4.7)
Treated with antihypertensives (%)a 32.5 32.0 44.9 - 4.0 ( - 9.0–1.7)
Stroke history (%) 3.3 2.8 15.5 4.7 (2.3–8.2)
Data are mean – SD or percent, a Including all beta blocker and diuretic drug use; b Adjusted for age and sex
Table 2. Association between NIDDM and dementia
Adjusted for age, and if applicable, sex Additional adjustmentsa
Total Men Women Total Men Women
NIDDM overall 1.3 (1.0–1.9) 0.9 (0.5– 1.8) 1.5 (1.0–2.2) 1.2 (0.9–1.8) 0.7 (0.3– 1.5) 1.5 (1.0–2.3)
no drug treatment 1.2 (0.8–1.9) 1.0 (0.4– 2.2) 1.4 (0.8–2.3) 1.2 (0.8–1.9) 0.8 (0.3– 2.0) 1.4 (0.8–2.5)
oral medication 1.2 (0.7–2.1) 0.5 (0.1– 2.2) 1.5 (0.8–2.6) 1.0 (0.6–1.8) 0.3 (0.1– 1.5) 1.3 (0.7–2.5)
insulin treatment 3.2 (1.4–7.5) 3.2 (0.7–16.0) 3.2 (1.2–8.7) 2.6 (1.1–6.2) 2.1 (0.4–11.5) 2.8 (1.0–7.6)
Data are odds ratio (95% confidence interval)
a Adjusted for education, smoking, body mass index, atherosclerosis, systolic blood pressure and antihypertensive drug treatment
The association could not be explained by an in-
creased prevalence of clinical strokes. The association
was found with vascular dementia and Alzheimer’s
disease (AD). In vascular dementia the relation ten-
ded to be stronger with more severe NIDDM,
whereas in AD an association was mainly found with
NIDDM treated with insulin.
Three possible biases need to be discussed. Firstly,
we did not obtain a 100% response. We do know
that non-responders were on average older than the
study participants. Dementia patients more often
had to be excluded due to incomplete diabetes infor-
mation. This, however, would only invalidate our re-
sults if the relation between NIDDM and dementia
was different among non-responders as compared to
participants, which we consider unlikely. Secondly,
because we studied the relation between diabetes
and dementia cross-sectionally, bias could have oc-
curred due to survival effects [27]. This could have re-
sulted in an overestimation of the relation if the rela-
tive decrease in survival due to diabetes would be
greater in non-demented than demented subjects or
in an underestimation if the combination of NIDDM
and dementia in a patient would interact and lead to
increased mortality. If anything, we consider the lat-
ter more likely. Thirdly, subtyping dementia, even if
based on generally accepted diagnostic criteria, re-
mains difficult and some misclassification cannot be
excluded. Furthermore, although the criteria for vas-
cular dementia are appropriate for identifying multi-
infarct dementia, they may fail to identify subjects in
whom other vascular mechanisms played an impor-
tant aetiological role, and vascular factors may also
be involved in AD [11, 23, 28, 29]. In the present
study AD was associated with NIDDM, particularly
when treated with insulin, even after exclusion of pa-
tients with cerebrovascular disease from the AD
group.
The relation of NIDDM with dementia was similar
between men and women only for NIDDM treated
with insulin. In untreated and tablet-treated NIDDM
a relation with dementia also seemed present in wo-
men but not in men. We do not know if this is simply
due to the low number of men with both NIDDM
and dementia, resulting in an unstable odds ratio
with wide confidence intervals or whether this
reflects a greater inpact of NIDDM on women. The
latter was suggested in a report from the Framingham
Heart Study, in which relatively more cardiovascular
disease was found in diabetic women than men [30].
Our results indicated that atherosclerosis had only
limited influence on the association between
NIDDM and dementia. However, we cannot com-
pletely exclude atherosclerosis as an aetiologic factor.
In order to investigate the relative contribution of
strokes we investigated the association in a subgroup
without history of stroke. Though the association
was also found in subjects without a history of stroke
it remains possible that silent infarctions due to
NIDDM pathology may underlie the excess of de-
mentia in diabetic subjects.
Our finding of an increased prevalence of vascular
dementia in diabetic patients is in line with results
from a study in which 175 multi-infarct dementia pa-
tients were compared with 125 age-matched neuro-
logically normal control subjects [31]. Diabetes was
2.8 times more prevalent in cases than in control sub-
jects. In a recent Japanese community-based study on
the incidence of dementia, it was shown that NIDDM
patients had an increased risk of developing vascular
dementia (age adjusted relative risk: 2.8) [15]. Fur-
thermore, Tatemichi et al. [32] showed that in stroke
patients, diabetes was associated with a higher rate
of dementia 3 months after the stroke (OR: 2.6).
Our findings of a relation between insulin-treated
NIDDM and AD contrasts with results of studies
which suggested that diabetes is less frequent among
AD patients than control subjects [12–14]. These
studies were relatively small, used selected clinical
AD cases, and geriatric clinic patients [12], vascular
dementia [13] or population control subjects [14].
Our results are in accordance with the Japanese Hi-
sayama Study which reported that NIDDM patients
had an increased risk of developing AD after 7 years
of follow-up (relative risk: 2.2, 95 % CI: 1.0–4.9) [15].
The relation between NIDDM and AD may be ex-
plained by diabetic vasculopathy and its sequelae.
The common coincidence of AD with cerebral infarc-
tions and subcortical white matter lesions [11, 33, 34]
suggests that vascular factors may be important in
AD. However, other and more direct mechanisms
could be involved. Recently, increased glycation of
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Table 3. Association between NIDDM and subtypes of dementia (adjusted for age and sex)
Alzheimer’s disease Vascular dementia
n = 44
Other dementias
n = 27Total
n = 194
Without CVD
n = 162
With CVD
n = 32
NIDDM overall 1.3 (0.9–1.9) 1.3 (0.9–2.0) 1.1 (0.4–2.7) 2.1 (1.1–4.0) 1.1 (0.4–2.9)
no drug treatment 1.3 (0.8–2.0) 1.3 (0.8–2.2) 0.9 (0.3–3.1) 1.1 (0.4–3.2) 1.5 (0.5–4.4)
oral medication 1.3 (0.6–2.0) 0.9 (0.5–2.0) 1.6 (0.5–5.5) 3.2 (1.4–7.4) no cases
insulin treatment 2.8 (1.0–8.0) 3.5 (1.2–9.8) no cases 5.4 (1.2–23.8) 3.5 (0.4–27.0)
Data are odds ratio (95% confidence interval)
CVD, cerebrovascular disease
proteins and advanced glycation end products
(AGE), which may be involved in the aetiology of di-
abetic complications, were found in plaques and tan-
gles of AD patients [35, 36]. AGE epitopes were
even detected in the earliest states of Alzheimer
brain lesions and do promote known plaque and tan-
gle properties. Progressive glycation augments the
deposition of proteins by crosslinking, it induces mac-
rophages to secrete acute-phase reactants, thereby
stimulating immune-cell response and it might con-
tribute to nerve-cell death by the formation of free
radicals [37, 38]. Alternatively, NIDDM effects on
neurotransmitter metabolism could contribute to
AD. In chronic diabetes, a considerable decline in
the blood-brain barrier transport of choline, a precur-
sor of acetylcholine, has been found [3]. Changes in
brain glucose utilisation or insulin-induced hypo-
glycaemic episodes might contribute to a reduced
acetylcholine synthesis [5, 39]. Blocking of acetylcho-
line muscarinic receptors is known to disrupt higher
cognitive functions and AD severity is correlated to
the loss of brain cholinergic activity [38, 39]. Finally,
we found that the correlation between NIDDM and
AD was strongest in NIDDM patients treated with
insulin. Most likely these patients had a more serious
and long-standing diabetes. It is however conceivable
that exogenous insulin itself or hypoglycaemic epi-
sodes which frequently complicate insulin therapy
[40] increase the risk of dementia and AD. A direct
correlation has been reported between increased en-
dogenous insulin level and impaired cognitive func-
tion [41].
In conclusion, we found that NIDDM, particularly
when treated with insulin, is associated with demen-
tia, both vascular dementia and AD. It is as yet un-
clear which pathophysiologic mechanisms could ex-
plain this association.
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